dolastatin
Peptideexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 1998 (NCT00005579)
Timeline
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dolastatin
- dolastatin
- dolastatin 10
- dolastatin 10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003914 | Phase 2 | Aug 1, 1999 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00003778 | Phase 2 | Apr 1, 1999 | National Cancer Institute (NCI), Temple University |
| NCT00003693 | Phase 1 | Mar 1, 1999 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00003677 | Phase 2 | Mar 1, 1999 | National Cancer Institute (NCI), University of Chicago, University of Texas at Houston |
| NCT00003557 | Phase 2 | Jan 1, 1999 | National Cancer Institute (NCI), University of Chicago |
| NCT00003626 | Phase 2 | Oct 1, 1998 | National Cancer Institute (NCI), Wayne State University |
| NCT00005579 | Phase 2 | Jun 1, 1998 | National Cancer Institute (NCI), University of Vermont |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 1 | 2 | 1998 |
| University of Chicago | Academic/Hospital | 2 | 1 | 1 | 1999 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 1999 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of Vermont | Academic/Hospital | 1 | 1 | 1 | 1998 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 1998 |
7 organizations
Page 1 / 1